Open access
Jul 2026
A multicomponent intervention incorporating CYP2C19 genotype-guided therapy and integrated pharmaceutical care reduces hospitalizations and improves adherence in ischemic stroke
A multicomponent intervention comprising CYP2C19 genotype-guided therapy and intensive pharmacist-led integrated pharmaceutical care significantly improved medication adherence and reduced hospitalization frequency, with more pronounced benefits observed in patients at high risk of stroke recurrence, without increasing the risk of adverse drug reactions.
Dan Zhang, Zhongru Meng, Yu-fei Li et al.
· Frontiers in Neurology · 0 citations